Selectively altering microbiota for immune modulation

• US 10,603,379 B2
• Filed: 06/26/2019
• Issued: 03/31/2020
• Est. Priority Date: 06/05/2016
• Status: Active Grant

• Current Assignee: Snipr Technologies Limited
• Original Assignee: Snipr Technologies Limited
• Inventors: Clube, Jasper, Sommer, Morten, Grondahl, Christian
• Primary Examiner(s): Nickol, Gary B
• Assistant Examiner(s): Jackson-Tongue, Lakia J
• Application Number:
  US16/453,609
• Publication Number:
  US 20190321470A1
• Time in Patent Office: 279 Days
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 31/7105 Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• CPC Class Codes: A61K 35/15 Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells presenting a specific antigen A61K39/00; therapeutic combinations of antibodies, or fragments thereof, and blood-derived cells A61K39/00
• CPC Class Codes: A61K 35/17 Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes when activated by a specific antigen A61K39/00
• CPC Class Codes: A61K 35/74 Bacteria therapeutic use of a bacterial protein A61K38/00
• CPC Class Codes: A61K 39/0011 Cancer antigens
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: C12N 2320/30 Special therapeutic applications
• CPC Class Codes: C12N 2320/50 Methods for regulating/modulating their activity

Abstract

The invention relates to methods of modulating immune cells in a patient by altering microbiota of the patient. The invention also relates to methods of modulating treatments or therapies in a subject organism by altering microbiota of the subject. The invention also relates to cell populations, systems, arrays, cells, RNA, kits and other means for effecting this. In an example, advantageously selective targeting of a particular species in a human gut microbiota using guided nucleic acid modification is carried out to effect the alteration.

Claims

1. A method for treating a cancer in a patient, wherein the method comprises

(a) exposing a microbiota in the patient to a guided nuclease to selectively target the genome of cells of a first species in the microbiota using the guided nuclease, wherein the first species is a bacterial or archaeal species;

and simultaneously or sequentially administering to the patient an effective amount of an immunotherapy; and

(b) allowing the guided nuclease to cut one or more target nucleotide sequences comprised by first cells of a first strain of the first species, thereby killing the first cells or reducing the growth thereof, whereby the proportion of the first cells comprised by the microbiota is reduced,

wherein;

the selective targeting avoids targeting second cells comprised by the microbiota, wherein the second cells are of a different strain or a different species from the first cells;

the reducing of the proportion of the first cells modulates immune cells in the patient, whereby the efficacy of the immunotherapy is enhanced for treatment of the cancer in the patient;

the immune cells comprise cells selected from CD8⁺ cells, tumor infiltrating lymphocytes (TILs), CD4⁺ cells, T_reg cells and memory cells;

the immune cells are upregulated or expanded in the patient; and

the immunotherapy comprises administration of an immune checkpoint modulator.

2. The method of claim 1, wherein the growth of the first cells is inhibited by at least 1000×

compared to the growth inhibition of the second cells 24 hours after exposing the first and second cells to the guided nuclease in an in vitro assay.

3. The method of claim 1, wherein the immune cells comprise CD8⁺ cells.

4. The method of claim 3, wherein the CD8⁺ cells are CD8⁺ cells of the patient.

5. The method of claim 1, wherein the immune checkpoint modulator is a PD-1 (programmed death-1) inhibitor, PD-L1 (programmed death-ligand 1) inhibitor or CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) inhibitor.

6. The method of claim 5, wherein the immune checkpoint modulator is selected from the group consisting of ipilimumab, tremelimumab, nivolumab, pembrolizumab, pidilizumab, BMS-936559, durvalumab, and atezolizumab.

7. The method of claim 1, wherein the first species is a gram negative bacterial species.

8. The method of claim 1, wherein the cancer is selected from the group consisting of lung cancer, melanoma, breast cancer, prostate cancer, colon cancer, renal cell carcinoma, ovarian cancer, neuroblastoma, rhabdomyosarcoma, leukaemia, lymphoma, non-small cell lung cancer (NSCLC), bladder carcinoma, and pancreatic cancer.

9. The method of claim 1, wherein the immune cells comprise memory cells selected from the group consisting of central memory T-cells (T_CM), effector memory T-cells (T_EM), stem cell memory cells (T_SCM), and memory effector T-cells (T_eff).

10. The method of claim 1, wherein the immune cells comprise memory cells selected from the group consisting of CD45RO⁺CD62L⁺ and CD25⁺CD45RA⁻

CD45RO⁺ CD127⁺ cells.

11. The method of claim 1, wherein the microbiota is a gut microbiota of the patient.

12. The method of claim 11, wherein the second cells are of a human gut commensal strain or a human gut probiotic strain.

13. The method of claim 1, wherein the immune cells comprise administered cells via adoptive cell therapy.

14. The method of claim 1, wherein the guided nuclease is a Cas, TALEN, meganuclease or zinc finger nuclease.

15. The method of claim 1, wherein the efficacy of the immunotherapy is enhanced by reducing or preventing the risk of an unwanted side effect of the immunotherapy, or reducing autotoxicity in the patient mediated by T_H2 cell cytokine release.

16. The method of claim 1, wherein the second cells have a 16s ribosomal RNA-encoding DNA sequence that is at least 80% identical to a 16s ribosomal RNA-encoding DNA sequence of the first cells.

17. The method of claim 1, wherein the patient is a human.

18. The method of claim 3, wherein the immune checkpoint modulator is a PD-1 (programmed death-1) inhibitor, PD-L1 (programmed death-ligand 1) inhibitor or CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) inhibitor.

19. The method of claim 3, wherein the first species is a gram negative bacterial species.

20. The method of claim 18, wherein the first species is a gram negative bacterial species.